Iron overload in β-thalassemia intermedia: an emerging concern
The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Abstract
Purpose of review The aim is to overview recent evidence on consequences, assessment, and management of iron overload in transfusion-independent patients with β-thalassemia intermedia. Recent findings Despite their transfusion-independence, β-thalassemia intermedia patients can still accumulate iron due to increased intestinal absorption. Recent observational studies show that iron burden in this group of patients can ultimately reach considerably high thresholds, and leads to a variety of serious morbidities involving the liver, endocrine glands, and arguably the vascular system. The diagnosis of iron overload in this patient population can follow established guidelines from β-thalassemia major patients, although with careful interpretation of spot serum ferritin levels. Data from a recent randomized clinical trial demonstrated the efficacy and safety of iron chelation therapy in decreasing liver iron concentration in this group of patients, which may ultimately help in reducing morbidity risk. Summary Iron overload in transfusion-independent patients with β-thalassemia intermedia deserves careful attention, and prompt diagnosis and management are recommended.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Anaemia owing to ineffective erythropoiesis, as occurs most prominently in patients with β-thalassaemia, is associated with severe iron overload that develops even in the absence of blood transfusions but is exacerbated in patients who receive repeated transfusions36,37.”
From Iron homeostasis in host defence and inflammation (2015) · cites this paper as [36]
Citations
Cites
Taher, A. T., Musallam, K. M., Karimi, M., El-Beshlawy, A., Belhoul, K., Daar, S., Saned, M.-S., El-Chafic, A.-H., Fasulo, M. R., & Cappellini, M. D. (2010) · Blood · doi:10.1182/blood-2009-09-243154 · Cited by 392 · cited 1×
“They may also require more frequent, yet temporary, transfusions in the case of poor growth or development during childhood, or for the management of specific complications in adulthood where the benefit of transfusion therapy has been established [2].”
BackgroundSelf-citationLiver iron concentrations and urinary hepcidin in -thalassemia
Origa, R., Galanello, R., Ganz, T., Giagu, N., Maccioni, L., Faa, G., & Nemeth, E. (2007) · Haematologica · doi:10.3324/haematol.10842 · Cited by 365 · cited 2×
“Increased intestinal iron absorption in thalassemia intermedia patients eventually leads to portal and hepatocyte iron loading [8], with subsequent release into the circulation of free iron species (nontransferrin-bound iron, NTBI) that are usually associated with target-organ damage [9].”
BackgroundHepcidin as a therapeutic tool to limit iron overload and improve anemia in β-thalassemic mice
Gardenghi, S., Ramos, P., Marongiu, M. F., Melchiori, L., Breda, L., Guy, E., Muirhead, K., Rao, N., Roy, C. N., Andrews, N. C., et al. (2010) · Journal of Clinical Investigation · doi:10.1172/jci41717 · Cited by 220 · cited 1×
“Studies on mouse models mimicking human thalassemia intermedia (exhibiting nontransfusion dependent anemia, aberrant erythrocyte morphology, hepatosplenomegaly, and iron overload) not only suggested a potential role for hepcidin and transferrin therapy to decrease iron overload but also showed beneficial effects on in…”
BackgroundOptimal management of β thalassaemia intermedia
Taher, A. T., Musallam, K. M., Cappellini, M. D., & Weatherall, D. J. (2011) · British Journal of Haematology · doi:10.1111/j.1365-2141.2010.08486.x · Cited by 207
Self-citationGinzburg, Y., & Rivella, S. (2011) · Blood · doi:10.1182/blood-2011-03-283614 · Cited by 201
Transferrin therapy ameliorates disease in β-thalassemic mice
Li, H., Rybicki, A. C., Suzuka, S. M., von Bonsdorff, L., Breuer, W., Hall, C. B., Cabantchik, Z. I., Bouhassira, E. E., Fabry, M. E., & Ginzburg, Y. Z. (2010) · Nature Medicine · doi:10.1038/nm.2073 · Cited by 192 · cited 1×
“Studies on mouse models mimicking human thalassemia intermedia (exhibiting nontransfusion dependent anemia, aberrant erythrocyte morphology, hepatosplenomegaly, and iron overload) not only suggested a potential role for hepcidin and transferrin therapy to decrease iron overload but also showed beneficial effects on in…”
BackgroundMusallam, K. M., Cappellini, M. D., Wood, J. C., Motta, I., Graziadei, G., Tamim, H., & Taher, A. T. (2011) · Haematologica · doi:10.3324/haematol.2011.047852 · Cited by 177
Self-citationDeletion of TMPRSS6 attenuates the phenotype in a mouse model of β-thalassemia
Nai, A., Pagani, A., Mandelli, G., Lidonnici, M. R., Silvestri, L., Ferrari, G., & Camaschella, C. (2012) · Blood · doi:10.1182/blood-2012-01-401885 · Cited by 161
Taher, A. T., Porter, J., Viprakasit, V., Kattamis, A., Chuncharunee, S., Sutcharitchan, P., Siritanaratkul, N., Galanello, R., Karakas, Z., Lawniczek, T., et al. (2012) · Blood · doi:10.1182/blood-2012-02-412692 · Cited by 147
Self-citationImpact of Iron Assessment by MRI
Wood, J. C. (2011) · Hematology · doi:10.1182/asheducation-2011.1.443 · Cited by 143
Research works printed but not linked: 3
- Taher, 2012, Haematologica, 96, 0924
- Taher, 2012, Blood, 120, 3258, 10.1182/blood-2012-02-412692 · DOI · Paper page
- Taher, 2012, Haematologica, 96, 0927
Cited by
Iron homeostasis in host defence and inflammation
Ganz, T., & Nemeth, E. (2015) · Nature Reviews Immunology · doi:10.1038/nri3863 · Cited by 843
Non-transfusion-dependent thalassemias
Musallam, K. M., Rivella, S., Vichinsky, E., & Rachmilewitz, E. A. (2013) · Haematologica · doi:10.3324/haematol.2012.066845 · Cited by 326
Self-citationFerritin: The Protein Nanocage and Iron Biomineral in Health and in Disease
Theil, E. C. (2013) · Inorganic Chemistry · doi:10.1021/ic400484n · Cited by 244
How I manage medical complications of β-thalassemia in adults
Taher, A. T., & Cappellini, M. D. (2018) · Blood · doi:10.1182/blood-2018-06-818187 · Cited by 145
Self-citationΑlpha-thalassemia: A practical overview
Musallam, K. M., Cappellini, M. D., Coates, T. D., Kuo, K. H. M., Al-Samkari, H. T., Sheth, S., Viprakasit, V., & Taher, A. T. (2024) · Blood Reviews · doi:10.1016/j.blre.2023.101165 · Cited by 117
Self-citationMusallam, K. M., Cappellini, M. D., Daar, S., Karimi, M., El-Beshlawy, A. M., Graziadei, G., Magestro, M., Wulff, J., Pietri, G., & Taher, A. T. (2014) · Haematologica · doi:10.3324/haematol.2013.097220 · Cited by 78
“The boundaries of these serum ferritin level groups are the recommended thresholds for tailoring iron chelation therapy in non-transfusion-dependent thalassemia patients including β-thalassemia intermedia.(2,5,6) Serum ferritin level was retrieved while patients were fasting and within the steady-state in the absence…”
BackgroundMethodSelf-citationGene Therapy for Hemoglobinopathies
Chandrakasan, S., & Malik, P. (2014) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2013.12.003 · Cited by 62
“(1) FV is nonpathogenic; (2) FV tends to integrate into nongenic regions predominantly; and (3) it has the largest retrovirus genome compared with RV and LV, hence can be used to package a larger transgene cassette.”
BackgroundEndocrine and Bone Complications inβ-Thalassemia Intermedia: Current Understanding and Treatment
Inati, A. C., Noureldine, M. H. A., Mansour, A. G., & Abbas, H. A. (2015) · BioMed Research International · doi:10.1155/2015/813098 · Cited by 66
Iron dysregulation in beta-thalassemia
Leecharoenkiat, K., Lithanatudom, P., Sornjai, W., & Smith, D. R. (2016) · Asian Pacific Journal of Tropical Medicine · doi:10.1016/j.apjtm.2016.07.035 · Cited by 59
Yanpanitch, O.-U., Hatairaktham, S., Charoensakdi, R., Panichkul, N., Fucharoen, S., Srichairatanakool, S., Siritanaratkul, N., & Kalpravidh, R. W. (2015) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2015/537954 · Cited by 57
Yadav, P. K., & Singh, A. K. (2022) · Plasmatology · doi:10.1177/26348535221103560 · Cited by 55
“Iron over-burden has additionally been seen in patients with NTDT (non-transfusion-subordinate thalassemia).(40) Beta-thalassemia with histidine to aspartic acid (H63D) experiences mutation in carriers patients, and iron overload at codon 63 of the HFE gene which indicates that the H63D mutation can influence the abso…”
BackgroundBarteselli, G., Dell’Arti, L., Finger, R. P., Issa, P. C., Marcon, A., Vezzola, D., Mapelli, C., Cassinerio, E., Cappellini, M. D., Ratiglia, R., et al. (2013) · Ophthalmology · doi:10.1016/j.ophtha.2013.10.016 · Cited by 53
Self-citationPattern of complications and burden of disease in patients affected by beta thalassemia major
Bonifazi, F., Conte, R., Baiardi, P., Bonifazi, D., Felisi, M., Giordano, P., Giannuzzi, V., Iacono, A., Padula, R., Pepe, A., et al. (2017) · Current Medical Research and Opinion · doi:10.1080/03007995.2017.1326890 · Cited by 49
Low Dose Iron Treatments Induce a DNA Damage Response in Human Endothelial Cells within Minutes
Mollet, I. G., Patel, D., Govani, F. S., Giess, A. P., Paschalaki, K. E., Periyasamy, M., Lidington, E. A., Mason, J. C., Jones, M. D., Gamé, L., et al. (2016) · PLoS ONE · doi:10.1371/journal.pone.0147990 · Cited by 48
“[2][3][4] In keeping with this, exposure of endothelial cells to very high iron concentrations (30–100μM) results in oxidative stress, apoptosis, proinflammatory, and prothrombotic responses.”
BackgroundChirico, V., Lacquaniti, A., Salpietro, V., Luca, N., Ferraù, V., Piraino, B., Luciana, R., Carmelo, S., & Arrigo, T. (2013) · European Journal of Endocrinology · doi:10.1530/eje-13-0627 · Cited by 48
Lertsuwan, K., Wongdee, K., Teerapornpuntakit, J., & Charoenphandhu, N. (2018) · The Journal of Physiological Sciences · doi:10.1007/s12576-018-0600-1 · Cited by 45
Morbidities in non‐transfusion‐dependent thalassemia
Saliba, A. N., & Taher, A. T. (2016) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.13083 · Cited by 35
Self-citationWinichakoon, P., Tantiworawit, A., Rattanathammethee, T., Hantrakool, S., Chai‐Adisaksopha, C., Rattarittamrong, E., Norasetthada, L., & Charoenkwan, P. (2015) · Anemia · doi:10.1155/2015/793025 · Cited by 33
Bahnasawy, S. M., Wakeel, L. M. E., El-Beblawy, N. M. S., & El‐Hamamsy, M. (2017) · Basic & Clinical Pharmacology & Toxicology · doi:10.1111/bcpt.12695 · Cited by 31
Haghpanah, S., Esmaeilzadeh, M., Honar, N., Hassani, F., Dehbozorgian, J., Rezaei, N., Abdollahi, M., Bardestani, M., Safaei, S., & Karimi, M. (2015) · Iranian Red Crescent Medical Journal · doi:10.5812/ircmj.17(5)2015.28343 · Cited by 30
“It is known that in patients with TI, there is also increased risk of iron over load due to increased intestinal iron absorption triggered by chronic anemia, ineffective erythropoiesis and decreased serum hepcidin (19, 20).”
BackgroundOlivera, J. D., Zhang, V., Nemeth, E., & Ganz, T. (2023) · Blood Advances · doi:10.1182/bloodadvances.2022009307 · Cited by 29
“Iron overload predominantly affects the liver.(10,23) The severity of the iron overload varies greatly even between unchelated patients of similar age and genotype.”
BackgroundOcular abnormalities in beta thalassemia patients: prevalence, impact, and management strategies
Heydarian, S., Jafari, R., Dailami, K. N., Hashemi, H., Jafarzadehpour, E., Heirani, M., Yekta, A., Mahjoob, M., & Khabazkhoob, M. (2019) · International Ophthalmology · doi:10.1007/s10792-019-01189-3 · Cited by 29
Shirley, M., & Plosker, G. L. (2014) · Drugs · doi:10.1007/s40265-014-0238-0 · Cited by 27
“Guidelines on the treatment of iron overload in NTDT patients are just emerging [11, 59].”
BackgroundVlachodimitropoulou, E., Mogharbel, H., Kuo, K. H. M., Hwang, M., Ward, R. A., Shehata, N., & Malinowski, A. K. (2024) · Blood Advances · doi:10.1182/bloodadvances.2023011636 · Cited by 22
Pathogenic Mechanisms in Thalassemia II
Ganz, T., & Nemeth, E. (2023) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2022.12.006 · Cited by 21
Glomerular and Tubular Functions in Children and Adults with Transfusion-Dependent Thalassemia
Annayev, A., Karakaş, Z., Karaman, S., Yalçıner, A., Yılmaz, A., & Emre, S. (2017) · Turkish Journal of Hematology · doi:10.4274/tjh.2017.0266 · Cited by 21
“In conclusion, patients with TDT may develop renal dysfunction.”
BackgroundInfluentialManagement of Non-Transfusion-Dependent Thalassemia: A Practical Guide
Taher, A. T., & Cappellini, M. D. (2014) · Drugs · doi:10.1007/s40265-014-0299-0 · Cited by 20
“However, LIC assessment is not always feasible and alternate serum ferritin level thresholds have been suggested [19, 68, 89, 90], partly since they have good predictive power for LIC (B300 ng/ ml for LIC of B3 mg Fe/g dw and C800 ng/ml for LIC of C5 mg Fe/g dw) [91, 92] and also since the two thresholds are associate…”
Self-citationSieg, H., Schaar, C., Fouquet, N., Böhmert, L., Thünemann, A. F., & Braeuning, A. (2024) · Toxicology in Vitro · doi:10.1016/j.tiv.2024.105772 · Cited by 17
Thalassemia Intermedia: Chelator or Not?
Lee, Y.-C., Yen, C.-T., Lee, Y.-L., & Chen, R.-J. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms231710189 · Cited by 17
“Two different mechanisms play a role in iron overload in TM and TI [6].”
BackgroundInfluentialMatin, S., Ghanei, M., Karemizadeh, Z., Haghpanah, S., Sanctis, V. D., Soliman, A. T., & Karimi, M. (2014) · Mediterranean Journal of Hematology and Infectious Diseases · doi:10.4084/mjhid.2015.005 · Cited by 17
Thiengtavor, C., Siriworadetkun, S., Paiboonsukwong, K., Fucharoen, S., Pattanapanyasat, K., Vadolas, J., Svasti, S., & Chaichompoo, P. (2019) · British Journal of Haematology · doi:10.1111/bjh.16295 · Cited by 16
Karimi, M., Arandi, N., Haghpanah, S., Ansari, S., Azarkeivan, A., Bordbar, M., & Safaei, S. (2015) · Hemoglobin · doi:10.3109/03630269.2015.1057735 · Cited by 13
“(2) also proposed a panel for management of iron overload in b-TI patients 10 years (2).”
BackgroundIron chelation therapy for non-transfusion-dependent thalassemia (NTDT): A status quo
Taher, A. T., Musallam, K. M., Viprakasit, V., Porter, J. B., & Cappellini, M. D. (2013) · Blood Cells Molecules and Diseases · doi:10.1016/j.bcmd.2013.08.006 · Cited by 13
Self-citationVitrano, A., Calvaruso, G., Tesè, L., Gioia, F. P., Cassarà, F., Campisi, S., Butera, F., Commendatore, V., Rizzo, M., Santoro, V., et al. (2016) · European Journal Of Haematology · doi:10.1111/ejh.12740 · Cited by 13
“This in turn leads to depletion of macrophage iron, relatively lower levels of serum ferritin, increased LIC and release into the circulation of free iron species that can cause target-organ damage (19).”
BackgroundAu, T. Y., Benjamin, S., & Wiśniewski, O. W. (2022) · Thalassemia Reports · doi:10.3390/thalassrep12030017 · Cited by 10
“The increased iron loading is the major cause of morbidity and mortality in patients with beta thalassemia major [16], although its detrimental role should also not be underestimated in transfusion-independent beta thalassemia intermedia [30].”
BackgroundGhazaiean, M., Aliasgharian, A., Karami, H., Ghasemi, M. M., & Darvishi‐Khezri, H. (2024) · Health Science Reports · doi:10.1002/hsr2.70096 · Cited by 4
“9 When transferrin becomes fully saturated, the surplus iron binds to low ‐ molecular ‐ weight ligands, forming non ‐ transferrin ‐ bound iron (NTBI).”
BackgroundTeawtrakul, N., Sirijerachai, C., Chansung, K., & Jetsrisuparb, A. (2021) · Hematology · doi:10.1080/16078454.2021.1943829 · Cited by 4
Association of depression and hydroxyurea use with neuropathic pain in hemoglobinopathies
Demiray, D. Y., & Oktay, G. (2025) · Scientific Reports · doi:10.1038/s41598-025-20590-w · Cited by 3
“Regular blood transfusions, which represent a cornerstone of thalassemia treatment, are known to cause micronutrient deficiencies—particularly in folic acid and vitamin B12—both of which play essential roles in maintaining nerve function 5–7 .”
Talasemilerde Solunum Sistemi Bozuklukları
Kazgan, T., & Küpeli, B. Y. (2017) · Arşiv Kaynak Tarama Dergisi · doi:10.17827/aktd.303592 · Cited by 3
Estimation of Iron Overload-Implications of its Non-linear Correlation
Chowdhury, P. K., & Saha, M. (2016) · Journal of Blood Disorders & Transfusion · doi:10.4172/2155-9864.1000360 · Cited by 2
“Chest XRays (P-A view) were suspicious in 3 patients, 3 had palpable, nontender and matted lymph nodes in the cervical region, and Mantaux test done with 5 TU (Tuberculin Test) tested Positive [7,8].”
BackgroundInfluentialAnnual Sickle Cell & Thalassaemia Conference (ASCAT) ‐ October 2024
(2024) · HemaSphere · doi:10.1002/hem3.70009 · Cited by 1
Shirinova, A., Asadov, C. D., Hasanova, A., & Alimirzoyeva, Z. (2026) · Cureus · doi:10.7759/cureus.102005 · Cited by 1
“Prior studies have suggested that genetic and metabolic factors in beta-thalassemia carriers, including chronic erythroid stress and variations in drug transporter gene expression, may affect pharmacokinetics and treatment response in myeloid malignancies [5,22,23].”
Mohamedahmed, K. A. (2026) · JOURNAL OF MEDICINE CARE AND HEALTH REVIEW · doi:10.61615/jmchr/2026/jan027140123 · Cited by 1
Tüfekçi, Ö., Atabay, B., Türker, M., Bengoa, Ş. Y., Gözmen, S., Karapınar, T. H., Ören, H., & İrken, G. (2017) · Journal of Pediatric Hematology/Oncology · doi:10.1097/mph.0000000000000914 · Cited by 1
Non-Transfusion Dependent Thalassemia: Translating Evidence to Guidelines
Harb, A., Saliba, A. N., & Taher, A. T. (2014) · Thalassemia Reports · doi:10.4081/thal.2014.4863 · Cited by 1
Self-citationMolecular Testing in Hemochromatosis
Brissot, P., Loréal, O., & Jouanolle, A. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-800886-7.00020-0 · Cited by 1
Cardiac Complications in Non-Transfusion Dependent Thalassaemia
Kabir, A. L., Irshadullah, N. M., & Rahman, M. (2020) · Haematology Journal of Bangladesh · doi:10.37545/haematoljbd201931 · Cited by 1
Rare Presentation of β-Thalassemia Intermedia With a Phenotype of Dilated Cardiomyopathy
Nakaya, Y., Higaki, A., Ochi, T., Nishikawa, T., Fujisawa, T., Miyazaki, S., Akazawa, Y., Miyoshi, T., Kawakami, H., Seike, F., et al. (2023) · CJC Open · doi:10.1016/j.cjco.2023.02.008 · Cited by 1
Baş, M. (2014) · Hacettepe University Institutional Repository (hacettepe.edu.tr) · Cited by 1
Изменение в костях при промежуточной β-талассемии
Gafarova, S. S. (2020) · EURASIAN JOURNAL OF CLINICAL SCIENCES · doi:10.28942/ejcs.v2i3.81
Ramadier, S. (2020) · theses.fr (ABES) · doi:10.70675/b75724f6zb386z4f05zae5dzc8f17b350499
Rehm, M. H., Rauf, A., Zulfiqar, I., Ali, A., Nazir, A., & Zehra, Q. (2023) · Pakistan Journal of Medical and Health Sciences · doi:10.53350/pjmhs20231711341
A Review of Cytokine Detection Methods in β-Thalassemia Major Patients
Alsamiri, A., Ismail, W. I., & Qadah, T. (2025) · Environment-Behaviour Proceedings Journal · doi:10.21834/e-bpj.v10isi35.7498
Khalid, F., Ashraf, B., & Ghazanfar, S. (2019) · Zenodo (CERN European Organization for Nuclear Research) · doi:10.5281/zenodo.3407086
Font-Monclus, I. (2015) · BOA (University of Milano-Bicocca)
Pathophysiology of Beta-Thalassaemia: (Part III) [Iron Overload]
Win, N. (2025) · Myanmar Medical Journal · doi:10.64455/xmma0013
La sérotonine intestinale : un acteur essentiel de la régulation de l'homéostasie du fer
Falabrègue, M. (2020) · theses.fr (ABES) · doi:10.70675/911bf09czfa11z4227zacfaz2f72ec7a7582
Quality of Life Among Adolescents and Adult Patients with Beta-Thalassemia Major in Karbala, Iraq
Amer, R., Jobori, S. S. A., & Ali, I. M. M. (2026) · Kufa Medical Journal · doi:10.36330/kmj.v22.i1.20316
Awadi, R., Benameur, N., Deriche, M. A., Fraj, I. B., Boukhriba, S., Taieb, A. B., Ouederni, M., & Labidi, S. (2026) · Diagnostics · doi:10.3390/diagnostics16142139
“Non-invasive assessment of myocardial iron using CMR-based techniques, such as T2* and T1 mapping, is well-established [16,35,36].”
Upadhyay, K., Nigam, N., Sinha, S., Verma, N., Chand, S., Gupta, A., & Nityanand, S. (2026) · Thalassemia Reports · doi:10.3390/thalassrep16030021
Metadata
- Authors
- Musallam, K. M., Cappellini, M. D., & Taher, A. T.
- Affiliations
- University of Milan (IT)
- American University of Beirut Medical Center (LB)
- Corresponding author
- Taher, Ali T.
- Venue
- Current Opinion in Hematology
- Published
- 2013-05
- Volume
- 20
- Issue
- 3
- Pages
- 187-192
- ISSN
- 1065-6251 (ISSN-L)
- OpenAlex
- W2064749326
- Cited by
- 50
- References
- 30
- Citations by year
- 2026: 3 · 2025: 3 · 2024: 3 · 2023: 3 · 2022: 3 · 2021: 1 · 2020: 1 · 2019: 2 · 2018: 2 · 2017: 6 · 2016: 6 · 2015: 6 · 2014: 6 · 2013: 5
- FWCI
- 1.05
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Current Opinion in Hematology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Genetics (clinical) › Hemoglobinopathies and Related Disorders
- Health Sciences › Medicine › Hematology › Iron Metabolism and Disorders
- Health Sciences › Medicine › Hematology › Hemophilia Treatment and Research
- Keywords
- iron overload, beta-thalassemia intermedia, intestinal iron absorption, serum ferritin, iron chelation therapy, liver iron concentration
- MeSH terms
- Humans, Iron Chelating Agents, beta-Thalassemia, Iron Overload
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.